Loading
A phase 3 trial of Amivantamab, Pembrolizumab, Carboplatin and Cisplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer is a phase 3 interventional study registered as NCT07276399 by Janssen Research & Development, LLC, with 500 participants planned, started 2025-12-03 and due to reach its primary completion in 2029-06-18. Interventions recorded: Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil and Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Platinum agents and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cisplatin, Carboplatin, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Platinum agents, Cisplatin, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Platinum agents, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/